How RA Capital Evaluates Biotech Investments

Every biotech investment, at its core, reduces to a question of conviction: do we believe this company can create enough value to justify the risk? At RA Capital, we’re nothing if not science-driven and evidence-based. Here we've distilled the key elements of how we assess biotech investment opportunities into a framework that our Investment and TechAtlas teams apply across public and private companies alike. 

It works like a formula: start with what an asset is worth if it succeeds, multiply by the probability that it will, divide by the time and money required to get there, and then multiply by how understandable the whole story is to the people who need to fund it. 

What’s it worth if it works

The first question we ask is straightforward: if everything goes right – the drug works, gets approved, and reaches patients – what is this company worth?

The inputs that drive this number higher are intuitive but demanding to estimate well. A larger addressable market lifts the ceiling. Higher rates of diagnosis and treatment mean more of that market is actually reachable. Gross margin matters – some kinds of medicines are simply more expensive to manufacture than others. Fewer competitors today or on the horizon means greater pricing power and greater market share. A longer patent life extends the window of exclusivity (though most drugs go generic after about 14 years on the market, as they are intended to by our patent system). And drugs that provide symptomatic relief tend to drive higher patient adherence, which sustains revenues over time. Each of these variables feeds into a model of future cash flows that, discounted back to today, tells us what the asset could be worth in the success scenario. Of course there are significant table stakes: the drug must be safe and effective to treat the intended population. 

This is the first half of the numerator – the prize, if everything breaks your way.

Probability of success

The second variable tempers the first: how likely is it that this drug actually works? Clinical development is full of binary, often brutal inflection points, and the probability of success at each stage shapes what an investor should be willing to pay today. The data aren’t difficult to find: most drugs that enter clinical trials fail somewhere on the way to an FDA approval. 

Certain features push that probability higher. A validated target – one with genetic or clinical evidence supporting its role in disease – is a strong starting point. A known and safe modality (such as a small molecule or monoclonal antibody) carries less platform risk than a first-in-class technology. Low placebo effects in the target indication make it easier to demonstrate a real treatment signal. The availability of biomarkers can allow for smaller, faster trials with clearer readouts. High unmet need often translates to more cooperative regulatory pathways. And multiple shots on goal – whether through backup compounds, combination strategies, or multiple indications – increase the cumulative odds that something in the program reaches the finish line.

Multiply the success-case value by the cumulative probability of reaching that outcome and you have the risk-adjusted value of the asset – what the industry calls the core of an rNPV calculation. But that product alone doesn't tell you whether the investment is a good one. You still need to know what it costs to get to the market and sell it once you get there.

Time and money

The denominator asks: how much time and capital will it take to create that value? Even if the risk-adjusted prize is large, a program that requires years of expensive trials, a complex manufacturing buildout, and a sprawling organization will burn through vast sums of capital and significant patent life before it delivers. The more time and money it takes, the less attractive the investment becomes – and the more things can go wrong along the way.

Programs that require smaller, fewer, or shorter trials cost less. Inexpensive manufacturing and lean teams preserve cash. A focused strategy avoids the trap of over-diversifying too early. High patient need can reduce marketing costs and accelerate uptake post-approval. On the time axis, adaptive trial designs, large patient populations that enable faster enrollment, and FDA bells-and-whistles that offer priority review and development pathways can all compress the timeline from investment to value creation. The less time and money required to reach a milestone, the better the ratio of reward to cost – and the more compelling the opportunity.

How easy is it to understand?

The final multiplier is the one that doesn't appear in any financial model but can make or break a company's trajectory: how perceivable is this opportunity to the broader investor community?

A drug program can score well on every other dimension – massive market, strong probability of success, capital-efficient plan – but if its story is too complex for enough investors to grasp, the company will struggle to raise capital on favorable terms. When too few people can evaluate the science or the commercial logic, financing becomes harder and more dilutive, regardless of the underlying merit. In the worst case, a great company gets stuck in a cycle of underfunding and undervaluation simply because its story doesn't travel well.

Simpler is better. Known comparables – both companies and products – give investors a frame of reference. Proof-of-concept data, controlled trials, objective endpoints, dose-response relationships, published literature, endorsements from key opinion leaders, credible executives, and smart co-investors all contribute to making an investment thesis legible. Understandability acts as a multiplier on everything else: a highly perceivable story amplifies the value of strong fundamentals, while an opaque one discounts them, sometimes severely.

The full equation

These four elements work together as a single calculation. The risk-adjusted value of an asset – what it's worth if it works, scaled by the probability that it does – is divided by the time and money required to realize that value, and then multiplied by how well the investment thesis can be understood and communicated to the people whose capital will fund the journey. The best investments score well across all four: large and defensible commercial potential, a credible path through clinical development, a capital-efficient plan to get there, and a story that others can underwrite. When we find those, we move with conviction.